

SUPPLEMENTARY DATA

Online-only Supplemental material

Medication adherence during adjunct therapy with statins and ACE inhibitors in adolescents with type 1 diabetes

Niechciał E, Acerini CL, Chiesa ST, Stevens T, Dalton RN, Daneman D, Deanfield JE, Jones TW, Mahmud FH, Marshall SM, Neil HAW, Dunger DB, Marcovecchio ML; on behalf of the Adolescent type 1 Diabetes cardio-renal Intervention Trial (AddIT) study group.

SUPPLEMENTARY DATA


Supplementary Table 1. Median adherence at the first and the last visit by sex, age, duration, HbA1C, countries

	Adherence at 1st visits (%)	Adherence at last visit (%)
Whole study population	92.9 (82.1-100.0)	76.7 (55.7-85.9)
Sex		
Female, n=203	92.9 (84.6-100.0)	79.6 (54.7-84.9)
Male, n=240	92.9 (80.0-100.0)	76.3 (56.6-90.1)
Age, years		
10 to 12, n=148	100.0 (85.7-100.0)	82.1 (70.9-86.0)
13 to 14, n=175	92.9 (78.6-100.0)	79.3 (60.8-92.)
15 to 17, n=120	92.6 (78.8-100.0)	73.0 (43.9-85.3)
Diabetes duration, years		
≤5, n=222	92.9 (80.0-100.0)	76.3 (62.4-84.8)
> 5 to 10, n=221	93.3 (83.3-100.0)	79.7 (43.5-92.9)
HbA1C % [mmol/mol]		
<7.5% [<58 mmol/mol], n=94	93.8 (85.7-100.0)	81.4 (69.0-92.9)
7.5-8.5% [58-69 mmol/mol], n=159	92.9 (82.7-100.0)	75.6 (63.3-84.8)
>8.5% [>69 mmol/mol], n=190	92.6 (78.6-100.0)	72.5 (47.3-87.6)
Diabetes treatment		
MDI, n=266	92.9 (81.8-100.0)	77.2 (47.3-85.7)
CSII, n=177	92.9 (82.7-100.0)	76.7 (61.6-87.5)
Country		
Australia, n=201	93.3 (85.7-100.0)	79.8 (64.4-86.5)
UK, n=118	92.9 (85.7-100.0)	76.1 (55.0-92.9)
Canada, n=124	89.0 (73.7-100.0)	73.0 (46.4-86.5)

Data are Median (interquartile range). CSII: continuous subcutaneous insulin infusion; MDI: multiple daily injections


SUPPLEMENTARY DATA

Supplementary Figure 1. Comparison of adherence rate between statin (ore related placebo) and ACE Inhibitors (ore related placebo) during the trial period



SUPPLEMENTARY DATA

Supplementary Figure 2. Adherence during the trial period based on MEMS for active study participants and for combined active and non-active participants




time (months)	1	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48
MEMS: only active participants	92.9	88.7	84.1	83.9	82.2	79.3	79.8	79.8	76.3	79.6	79.5	78.3	79.0	80.8	77.8	77.6	76.3
MEMS: active and non-active participants	92.9	87.4	82.8	82.7	80.0	77.0	75.9	73.0	70.1	73.6	74.4	73.3	73.3	74.7	70.0	70.6	70.2

Results at each study visit are reported as medians. P for over time trend <0.001
 For non-active participants at any specific time point, adherence was set equal to 0

SUPPLEMENTARY DATA

Supplementary Figure 3. Adherence by HbA1c groups during the trial period



Lines are median levels of adherence for each HbA1c group: <7.5% (<58 mmol/mol); 7.5-8.5% (58-69 mmol); >8.5% (>69 mmol/mol).

SUPPLEMENTARY DATA

1. Adolescent type 1 Diabetes cardio-renal Intervention Trial (AddIT) study group:

Carlo L. Acerini (University of Cambridge, Cambridge, UK), **Frank Ackland** (Northampton General Hospital, Northampton, UK), **Binu Anand** (West Suffolk Hospital, NHS Foundation Trust, Bury St Edmunds, UK), **Tim Barrett** (Birmingham Children's Hospital and University of Birmingham, Birmingham, UK), **Virginia Birrell** (James Cook Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK), **Fiona Campbell** (Leeds General Infirmary, The Leeds Teaching Hospitals NHS Trust, Leeds, UK), **Marietta Charakida** (King's College London, London, UK), **Tim Cheetham** (Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, UK), **Scott T. Chiesa** (University College London, London, UK), **John E. Deanfield** (University College London, London, UK), **Chris Cooper** (Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UK), **Ian Doughty** (Royal Manchester Children's Hospital, Manchester, UK), **Atanu Dutta** (Stoke Mandeville Hospital, Aylesbury, UK), **Julie Edge** (John Radcliffe Hospital, Oxford, UK), **Alastair Gray** (University of Oxford, Oxford, UK), **Julian Hamilton-Shield** (University of Bristol and University Hospitals Bristol NHS Foundation Trust, Bristol, UK), **Nick Mann** (Royal Berkshire Hospital, Reading, UK), **M. Loredana Marcovecchio** (University of Cambridge, Cambridge, UK), **Sally M. Marshall** (Newcastle University), **H. Andrew W. Neil** (University of Oxford, Oxford, UK), **Gerry Rayman** (Ipswich Hospitals NHS Trust, Ipswich, UK), **Jonathon M. Robinson** (Royal Albert Edward Infirmary, Wroughton, Wigan and Leigh NHS Foundation Trust, Wigan, UK), **Michelle Russell-Taylor** (Wycombe Hospital, Buckingham Healthcare NHS Trust, High Wycombe, UK), **Vengudi Sankar** (Royal Bolton Hospital, Bolton NHS Foundation Trust, Bolton, UK), **Anne Smith** (Northampton General Hospital, Northampton, UK), **Nandu Thalange** (Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK), **Chandan Yaliwal** (Royal Berkshire Hospital, Reading, UK).

Paul Benitez-Aguirre (The Children's Hospital at Westmead and University of Sydney, Sydney, NSW, Australia), **Fergus Cameron** (Royal Children's Hospital, Murdoch Children's Research Institute and The University of Melbourne, Melbourne, VIC, Australia), **Andrew Cotterill** (University of Queensland, Brisbane, QLD, Australia), **Jennifer Couper** (Women's and Children's Hospital and University of Adelaide, Adelaide, SA, Australia), **Maria Craig** (The Children's Hospital at Westmead, University of Sydney, and University of New South Wales, Sydney, NSW, Australia), **Elizabeth Davis** (Princess Margaret Hospital for Children and University of Western Australia, Perth, WA, Australia), **Kim Donaghue** (The Children's Hospital at Westmead and University of Sydney, Sydney, NSW, Australia), **Timothy W. Jones** (Princess Margaret Hospital for Children and University of Western Australia, Perth, WA, Australia), **Bruce King** (University of Newcastle, Newcastle, NSW, Australia), **Charles Verge** (Sydney Children's Hospital and University of New South Wales, Sydney, NSW, Australia), **Phil Bergman** (Monash Children's Hospital, Clayton, VIC, Australia), **Christine Rodda** (University of Melbourne, Melbourne, VIC, Australia).

Cheril Clarson (London Health Sciences Centre and Western University, London, ON, Canada); **Jacqueline Curtis** (The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada), **Denis Daneman** (The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada), **Farid H. Mahmud** (The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada); **Etienne Sochett** (The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada).

2. AddIT TRIAL STEERING COMMITTEE MEMBERS

Chair-Prof Sally Marshall (Newcastle University); Prof Jane Armitage (University of Oxford); Prof Polly Bingley (University of Bristol), Prof William Van't Hoff (Great Ormond Street Hospital, London), Prof David Dunger (University of Cambridge), Prof Neil Dalton (King's College London), Prof Denis

SUPPLEMENTARY DATA

Daneman (University of Toronto), Prof Andrew Neil (University of Oxford), Prof John Deanfield (University College London), Prof Tim Jones, (University of Western Australia), Prof Kim Donaghue (University of Sydney)

3. ADDIT DATA MONITORING AND ETHICS COMMITTEE MEMBERS

Chair- Prof Colin Baigent (University of Oxford); Dr Jon Emberson (University of Oxford); Prof Marcus Flather (University of East Anglia Norwich); Professor Rudy Bilous (James Cook University Hospital, Middlesbrough).

4. ADDIT STUDY COORDINATORS:

Stella Silvester and Rowena Weighell, University of Cambridge, UK; Yesmino Elia, The Hospital for Sick Children, Toronto, Canada; Dr Charles Czank, Telethon Institute for Child Health Research, University of Western Australia, Perth, Australia.